Effect of entecavir combined with Fufangbiejiaruangan treatment in patients with chronic hepatitis B

doi:10.3877/cma.j.issn.1674-1358.2017.06.017

Abstract

Abstract:

Objective

To investigate the clinical therapeutic effect of entecavir combined with Fufangbiejiaruangan in patients with chronic hepatitis B (CHB).

Methods

Total of 160 patients with CHB diagnosed and treated in our hospital from June 2012 to April 2015 were collected, and were divided into control group (80 cases) and observation group (80 cases) by random number method. The patients in control group were treated with entecavir, while the patients in observation group were treated with entecavir and Fufangbiejiaruangan tablet. The rates of clinical efficacy of the two groups were compared.

Results

After treatment, the levels of ALT, AST and total bilirubin (TBil) of patients in observation group [(31.2 ± 19.4) U/L, (34.9 ± 21.5) U/L and (16.3 ± 7.0) μmol/L] were significantly lower than those of patients in the control group [ (47.8 ± 32.1) U/L, (48.8 ± 42.1) U/L and (17.1 ± 8.3) μmol/L], with significant difference, respectively (t = 16.348, 19.284, 17.395; P = 0.032, 0.042, 0.026). The level of ALB in patients in observation group [ (43.8 ± 4.5) g/L] was significantly higher than that of the control group; the levels of serum HA, LN, HBV DNA, PC-Ⅲ and Ⅳ-C of patients in the observation group were significantly lower than those in the control group, with significant difference (all P < 0.05). After 48 weeks of treatment, the incidence of adverse reactions in the observation group was 7.5%, significantly lower than that of the control group (P = 0.041, χ² = 6.31).

Conclusions

Patients with CHB treated with entecavir combined with Fufangbiejiaruangan could get better clinical efficacy.

Key words: Entecavir, Fufangbiejiaruangan, Chronic hepatitis B, Treatment effect

Ping Huang, Gaoxiong Yang, Xin Huang, Long Lin. Effect of entecavir combined with Fufangbiejiaruangan treatment in patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(06): 603-606.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.06.017

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I06/603

Figures/Tables 3

References 25

[1]	高海丽, 王宏伟, 梁海军, 等. 恩替卡韦联合三甲益肝颗粒治疗慢性乙型肝炎抗肝纤维化的效果观察[J]. 中国医药导报,2013,10(35):102-105.
[2]	Qu J, Yu Z, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial[J]. Trials,2014,15(1):438.
[3]	肖玲, 杨玉宇. 徐莉恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床效果观察[J]. 药物与临床,2013,3(14):59-60.
[4]	Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis[J]. Am J Physiol Cell Physiol,2013,305(8):C789-C799.
[5]	陈祥安, 赵青山, 谢超华. 拉米呋定联合复方鳖甲软肝片治疗早期乙肝肝硬化的疗效观察[J]. 国际医药卫生导报,2014,20(15):2335-2337.
[6]	吴刚, 何鸿雁, 李烨, 等. 复方鳖甲软肝片联合恩替卡韦对HBV相关肝硬化患者的临床疗效观察[J]. 中华肝脏病杂志,2014,22(8):604-608.
[7]	何莹. 替比夫定联合复方鳖甲软肝片治疗乙型肝炎疗效观察[J]. 吉林医学,2013,34(11):2050-2051.
[8]	Kim MN, Kim SU, Kim BK, et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir[J]. Liver Int,2014,34(8):1216-1223.
[9]	恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识: 2015年更新[J]. 临床肝胆病杂志,2016,32(1):32-39.
[10]	郭文强. 复方鳖甲软肝片联合恩替卡韦治疗乙肝后肝硬化随机平行对照研究[J]. 实用中医内科杂志,2013,27(5):111-112.
[11]	Poortahmasebi V, Alavian SM, Keyvani H, et al. Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis Binfection[J]. Asian Pac J Cancer Prev,2014,15(9):3879-3884.
[12]	王术梅, 张红. 拉米夫定联合α-干扰素治疗慢性乙型肝炎疗效观察[J]. 中国冶金工业医学杂志,2014,31(3):297-298.
[13]	区淑华, 石梅彬. 恩替卡韦治疗HBeAg阳性慢性乙型肝炎相关影响因素分析(附56例报告)[J]. 贵州医药,2014,38(1): 72-75.
[14]	李学全. 拉米夫定联合复方鳖甲软肝片对乙型肝炎患者细胞因子及纤维化指标的影响[J]. 河北医学,2012,34(3):376.
[15]	姚云洁, 杨才兴, 巫继. 恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎患者疗效观察[J]. 实用肝脏病杂志,2015,18(4): 356-359.
[16]	张瑞凤, 姚云洁, 游忠岚, 等. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化的观察[J]. 第三军医大学学报,2014,36(18): 1961-1963.
[17]	方祖毅, 方文. 阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型病毒性肝炎患者肝纤维化的疗效[J]. 河北医学,2013,19(9):1284-1287.
[18]	Su TH, Kao JH. Improving clinical outcomes of chronic hepatitis Bvirus infection[J]. Expert Rev Gastroenterol Hepatol,2015,9(2):141-54.
[19]	肝脏硬度评估小组. 瞬时弹性成像技术诊断肝纤维化专家意见[J]. 中华肝脏病杂志,2013,21(6):420-424.
[20]	Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™)and transient elastography (FibroScan®)[J]. J Hepatol,2014,60(4):706-714.
[21]	赵洪伟, 刘福全, 岳振东, 等. 应用覆膜支架TIPS治疗不同类型慢性门静脉血栓术后肝性脑病发生探讨[J]. 介入放射学杂志,2014,23(8):672-678.
[22]	赵洪伟, 刘福全, 岳振东, 等. 经颈静脉途径介入性干预TIPS分流后肝性脊髓病的临床疗效评价[J]. 中华放射学杂志,2013,47(1):239-244.
[23]	刘福全, 岳振东, 赵洪伟, 等. 经颈静脉肝内门-体分流术后再次介入治疗肝硬化门静脉高压长期疗效及再次手术原因分析[J]. 中华放射学杂志,2012,46(1):830-835.
[24]	Mayorga CA, Rockey DC. Clinical utility of a standardized electronic order set for the management of acute upper gastrointestinal hemorrhage in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2013,11(10):1342-1348.
[25]	屠红辉, 纪礽斌. 复方鳖甲软肝片联合慢肝解郁胶囊对肝硬化代偿期患者的疗效及安全性观察[J]. 辽宁中医杂志,2014,41(6):1163-1164.

组别	ALT（U/L）		AST（U/L）		TBil（μmol/L）		ALB（g/L）
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	114.7 ± 70.9	31.2 ± 19.4	95.8 ± 61.5	34.9 ± 21.5	22.7 ± 7.4	16.3 ± 7.0	38.1 ± 3.1	43.8 ± 4.5
对照组	116.3 ± 70.4	47.8 ± 32.1	96.3 ± 64.8	48.8 ± 42.1	22.1 ± 7.8	17.1 ± 8.3	38.4 ± 3.8	38.9 ± 4.3
t值	0.385	16.348	1.835	19.284	0.846	17.395	1.261	17.491
P值	0.078	0.032	0.091	0.042	0.068	0.026	0.068	0.017

组别	ALT（U/L）		AST（U/L）		TBil（μmol/L）		ALB（g/L）
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	114.7 ± 70.9	31.2 ± 19.4	95.8 ± 61.5	34.9 ± 21.5	22.7 ± 7.4	16.3 ± 7.0	38.1 ± 3.1	43.8 ± 4.5
对照组	116.3 ± 70.4	47.8 ± 32.1	96.3 ± 64.8	48.8 ± 42.1	22.1 ± 7.8	17.1 ± 8.3	38.4 ± 3.8	38.9 ± 4.3
t值	0.385	16.348	1.835	19.284	0.846	17.395	1.261	17.491
P值	0.078	0.032	0.091	0.042	0.068	0.026	0.068	0.017

组别	HA		LN		PC-Ⅲ		Ⅳ-C
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	217.4 ± 56.4	133.1 ± 35.8	108.4 ± 33.2	70.5 ± 25.3	75.9 ± 23.1	44.3 ± 14.9	78.5 ± 21.0	45.8 ± 12.4
对照组	216.1 ± 55.7	164.2 ± 32.5	70.5 ± 25.3	86.4 ± 20.1	74.2 ± 22.9	57.4 ± 12.9	78.8 ± 21.5	59.5 ± 13.5
t值	0.182	20.441	1.273	21.294	0.536	17.483	1.241	19.461
P值	0.074	0.043	0.081	0.032	0.055	0.019	0.084	0.027

组别	HA		LN		PC-Ⅲ		Ⅳ-C
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	217.4 ± 56.4	133.1 ± 35.8	108.4 ± 33.2	70.5 ± 25.3	75.9 ± 23.1	44.3 ± 14.9	78.5 ± 21.0	45.8 ± 12.4
对照组	216.1 ± 55.7	164.2 ± 32.5	70.5 ± 25.3	86.4 ± 20.1	74.2 ± 22.9	57.4 ± 12.9	78.8 ± 21.5	59.5 ± 13.5
t值	0.182	20.441	1.273	21.294	0.536	17.483	1.241	19.461
P值	0.074	0.043	0.081	0.032	0.055	0.019	0.084	0.027

组别	例数	恶心呕吐	眩晕	疲劳	发生率
观察组	80	2（2.5）	4（5.0）	0（0.0）	6（7.5）
对照组	80	4（5.0）	6（7.5）	6（7.5）	16（20.0）
χ²值		3.890	3.890	5.820	6.310
P值		0.024	0.024	0.035	0.041

Please choose a citation manager

Content to export